125 eller 250 mg to gange dagligt) var de mest almindelige bivirkninger, som optrådte hyppigere hos patienter, der fik Tracleer, end hos dem, der fik placebo (hos ≥ 3% af patienter, der blev behandlet med Tracleer med ≥ 2% forskel) infektion i de øvre luftveje, hypotension og anæmi.
At the recommended maintenance dose or double the dose (i.e., 125 or 250 mg twice daily) the adverse drug reactions that occurred more frequently with Tracleer than with placebo (in ≥ 3% of Tracleer-treated patients, with ≥ 2% difference) were upper respiratory tract infection, hypotension, and anaemia.